Niagen Bioscience (NAGE) Amortization of Deferred Charges (2019)
Niagen Bioscience (NAGE) reported Amortization of Deferred Charges of $294000.0 for Q3 2019, down 28.99% quarter-over-quarter from $414000.0 in Q2 2019.
Niagen Bioscience (NAGE) Amortization of Deferred Charges (2019) Analysis & Trends
Niagen Bioscience (NAGE) has 1 years of Amortization of Deferred Charges data on file, last reported at $294000.0 in Q3 2019.
- Amortization of Deferred Charges for Q3 2019 came in at $294000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $846000.0 (changed N/A YoY), and the FY2019 annual result was $846000.0, changed N/A from the prior year.
- Amortization of Deferred Charges slipped to $294000.0 in Q3 2019 per NAGE's latest filing, from $414000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $414000.0 in Q2 2019 and troughed at $138000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 294,000.00 |
| Sep 30, 2019 | 294,000.00 |
| Jun 30, 2019 | 414,000.00 |
| Jun 30, 2019 | 414,000.00 |
| Mar 31, 2019 | 138,000.00 |
| Mar 31, 2019 | 138,000.00 |